CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-64213 | Pharmaceuticals and Healthcare
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Cancer Monoclonal Antibody Partnering Terms and Agreements Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET
7.1 GLOBAL CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODY PARTNERING TERMS AND AGREEMENTS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 3SBio
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 4D Pharma
16.3 Abbvie
16.4 Abzena
16.5 Adaptive Biotechnologies
16.6 Aeglea BioTherapeutics
16.7 Agenus Bio
16.8 Ascension
16.9 Ascentage Pharma
16.10 Aslan Pharma
16.11 Telix Pharmaceuticals
16.12 Basilea Pharmaceutica
16.13 Bavarian Nordic
16.14 Baxalta
16.15 Bayer
16.16 Cantargia
16.17 Apollomics
16.18 Chiome Bioscience
16.19 Clovis Oncology
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeAsset Purchase
Collaborative R&D
Joint Venture
Licensing
By Application
Pharmaceutical Industry
Biotechnology
Medical Care
Education and Research
Companies
3SBio
4D Pharma
Abbvie
Abzena
Adaptive Biotechnologies
Aeglea BioTherapeutics
Agenus Bio
Ascension
Ascentage Pharma
Aslan Pharma
Telix Pharmaceuticals
Basilea Pharmaceutica
Bavarian Nordic
Baxalta
Bayer
Cantargia
Apollomics
Chiome Bioscience
Clovis Oncology
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.